Pestronk Lab
Alan Pestronk, MD
Focused on neuromuscular disorders through clinical and research efforts. The lab investigates conditions like myopathy, neuropathy and myasthenia gravis, emphasizing neuroimmunology, aging and molecular mechanisms to improve diagnosis and treatment.
Learn more on the Neuromuscular Disease Center website »
Principal investigator
Our team
Recent publications
- Gene therapy ameliorates neuromuscular pathology in CLN3 diseaseZiółkowska, E. A., Jablonka-Shariff, A., Williams, L. L., Jansen, M. J., Wang, S. H., Eultgen, E. M., Wood, M. D., Hunter, D. A., Sharma, J., Sardiello, M., Reese, R., Pestronk, A., Sands, M., Snyder-Warwick, A. & Cooper, J. D., Dec 2025, In: Acta Neuropathologica Communications. 13, 1, 160.Research output: Contribution to journal › Article › peer-review
- Dysferlinopathy as cause of long-term hyperCKemia with preserved strengthCheema, I., Goodwin, J., Liewluck, T., Bucelli, R. C., Pestronk, A. & Milone, M., Dec 2025, In: Orphanet Journal of Rare Diseases. 20, 1, 317.Research output: Contribution to journal › Article › peer-review
- In memoriam: Dr. Julaine Marie Florence (1953–2025)Weihl, C. C., Connolly, A., King, W. & Pestronk, A., Sep 2025, In: Neuromuscular Disorders. 54, 106207.Research output: Contribution to journal › Letter › peer-review
- High-Density Lipoprotein-Associated Cholesterol Abnormalities in a Clinical Outcomes Study of Dysferlin-Deficient Limb–Girdle Muscular Dystrophy Type R2The Jain COS Consortium, Aug 2025, In: Journal of Cachexia, Sarcopenia and Muscle. 16, 4, e70042.Research output: Contribution to journal › Article › peer-review
- Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe diseaseon behalf of the PROPEL Study Group, Dec 2024, In: Journal of Patient-Reported Outcomes. 8, 1, 132.Research output: Contribution to journal › Article › peer-review